Net Savings Link Inc (OTCMKTS:NSAV) reported that its subsidiary unit, Vital Strategic Research Institute will advance and deploy Blockchain Technology to enhance the quality of its clinical research. The firm considers that Blockchain will offer it with a significant benefit over the competition. VSRI marks as a medical research company with an extensive history of expertise in design, global research and clinical trials. It has collaborated with pharma giants such as Bristol-Myers Squibb Co (NYSE:BMY) and Pfizer Inc. (NYSE:PFE).
In December, VSRI finalized a major deal with Eli Lilly and firm. Under the terms of the deal, VSRI will offer Eli Lilly with an evaluation of Cardio Vascular Disease among newly known diabetes patients at higher risk of CVD in China. As it is known, China is facing the major diabetes epidemic across the world with nearly 11% of its population struggling with the metabolic illness, while almost 36% are pre-diabetic. The recent updates show that CVD in China has reached epidemic proportions, with more than 200 million residents suffering from the world’s major cause of death.
James Tilton, the President of Net Savings Link, expressed that he is extremely delighted that they will be adding Blockchain Technology to their clinical research operations. It took some time, however the medicinal community is finally realizing the advantages of Blockchain in clinical trials and clinical research and he is excited that company will be leading this revolution.
Net Savings Link’s vision is the formation of a fully integrated know-how and software firm that offers turnkey software and technological solutions to the medical market. Over time, the firm intends to offer a wide range of services including software solutions, advisory services, e-commerce, patents, trademarks, information technology and financial services. In unrelated news, the company reported that Medtronic PLC will be the major sponsor and partner of the firm’s Heart Rescue Project.